- Home
- TCBX vs FULC Comparison
TCBX vs FULC Comparison
Compare TCBX & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCBX | FULC |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.8M | 468.1M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TCBX | FULC |
|---|---|---|
| Price | $38.81 | $10.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $41.67 | $16.38 |
| AVG Volume (30 Days) | 78.6K | ★ 1.4M |
| Earning Date | 01-21-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.90 | N/A |
| EPS | ★ 3.56 | N/A |
| Revenue | ★ $192,224,000.00 | N/A |
| Revenue This Year | $24.66 | N/A |
| Revenue Next Year | $17.56 | N/A |
| P/E Ratio | $10.67 | ★ N/A |
| Revenue Growth | 20.96 | ★ 2752.05 |
| 52 Week Low | $25.17 | $2.32 |
| 52 Week High | $41.70 | $15.74 |
Technical Indicators
Market Signals| Indicator | TCBX | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 49.00 | 41.73 |
| Support Level | $37.56 | $9.77 |
| Resistance Level | $38.94 | $12.27 |
| Average True Range (ATR) | 1.13 | 0.70 |
| MACD | -0.21 | -0.34 |
| Stochastic Oscillator | 37.73 | 12.14 |
Price Performance
Historical ComparisonAbout TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates eleven branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.